Literature DB >> 15090958

Albumin influences total plasma antioxidant capacity favorably in patients with acute lung injury.

Gregory J Quinlan1, Sharon Mumby, Greg S Martin, Gordon R Bernard, John M C Gutteridge, Timothy W Evans.   

Abstract

OBJECTIVE: To ascertain the influence of albumin on antioxidant status in patients with acute lung injury.
DESIGN: Prospective, randomized, placebo-controlled study.
SETTING: Intensive care units, teaching hospitals. PATIENTS: Twenty patients meeting the American European Consensus criteria for acute lung injury.
INTERVENTIONS: Ten patients received albumin (25 g of a 25% solution every 8 hrs for a total of nine doses) and ten received placebo (normal saline administered in identical fashion and volume). All received supportive therapy appropriate for patients with acute lung injury. Plasma samples were obtained sequentially from all patients before, 30 mins after, and 4 hrs after albumin/placebo administration.
MEASUREMENTS AND MAIN RESULTS: Serum albumin and total protein, total antioxidant status, iron-binding antioxidant protection, iron-oxidizing antioxidant protection, lipid hydroperoxides, protein carbonyls, and plasma thiols were measured. Albumin administration increased plasma albumin concentrations (p <.05 compared with placebo) and decreased concentrations of protein carbonyls (p <.05 compared with placebo). By contrast, plasma lipid hydroperoxide concentrations were similar in both groups, both in absolute terms and relative to albumin content. For all other variables, no significant differences were apparent. For all patients, there was a positive correlation between albumin and plasma thiol concentrations (r =.983, p <.01) and albumin and antioxidant capacity (r =.885, p =.01). In the albumin treatment group, there was a strong correlation between thiols and antioxidant capacity (r =.876, p =.01). No such correlation was apparent in the placebo group. Plasma iron-binding antioxidant protection was negatively correlated (r = -.741, p <.05) with albumin content in the treatment group but not the placebo group.
CONCLUSIONS: In patients with acute lung injury, albumin administration favorably influences plasma thiol-dependent antioxidant status as well as levels of protein oxidative damage.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15090958     DOI: 10.1097/01.ccm.0000114574.18641.5d

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  40 in total

Review 1.  Human albumin solution for resuscitation and volume expansion in critically ill patients.

Authors:  Ian Roberts; Karen Blackhall; Phil Alderson; Frances Bunn; Gillian Schierhout
Journal:  Cochrane Database Syst Rev       Date:  2011-11-09

2.  Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis.

Authors:  Simon Finfer; Suzanne McEvoy; Rinaldo Bellomo; Colin McArthur; John Myburgh; Robyn Norton
Journal:  Intensive Care Med       Date:  2010-10-06       Impact factor: 17.440

Review 3.  Clinical use of albumin in hepatology.

Authors:  Matteo Garcovich; Maria Assunta Zocco; Antonio Gasbarrini
Journal:  Blood Transfus       Date:  2009-10       Impact factor: 3.443

Review 4.  In my opinion: serum albumin should be maintained during neurocritical care.

Authors:  David J Powner
Journal:  Neurocrit Care       Date:  2011-06       Impact factor: 3.210

5.  5 Human Albumin.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

6.  The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities.

Authors:  Cristina Gutierrez; Anne Rain T Brown; Megan M Herr; Sameer S Kadri; Brian Hill; Prabalini Rajendram; Abhijit Duggal; Cameron J Turtle; Kevin Patel; Yi Lin; Heather P May; Alice Gallo de Moraes; Marcela V Maus; Mathew J Frigault; Jennifer N Brudno; Janhavi Athale; Nirali N Shah; James N Kochenderfer; Ananda Dharshan; Amer Beitinjaneh; Alejandro S Arias; Colleen McEvoy; Elena Mead; R Scott Stephens; Joseph L Nates; Sattva S Neelapu; Stephen M Pastores
Journal:  J Crit Care       Date:  2020-04-15       Impact factor: 3.425

7.  Impact of serum albumin levels on long-term outcomes in patients undergoing percutaneous coronary intervention.

Authors:  Hideki Wada; Tomotaka Dohi; Katsumi Miyauchi; Jun Shitara; Hirohisa Endo; Shinichiro Doi; Ryo Naito; Hirokazu Konishi; Shuta Tsuboi; Manabu Ogita; Takatoshi Kasai; Shinya Okazaki; Kikuo Isoda; Satoru Suwa; Hiroyuki Daida
Journal:  Heart Vessels       Date:  2017-04-20       Impact factor: 2.037

8.  The Albumin in Subarachnoid Hemorrhage (ALISAH) multicenter pilot clinical trial: safety and neurologic outcomes.

Authors:  Jose I Suarez; Renee H Martin; Eusebia Calvillo; Catherine Dillon; Eric M Bershad; R Loch Macdonald; John Wong; Robert Harbaugh
Journal:  Stroke       Date:  2012-01-19       Impact factor: 7.914

9.  Effect of baseline serum albumin concentration on outcome of resuscitation with albumin or saline in patients in intensive care units: analysis of data from the saline versus albumin fluid evaluation (SAFE) study.

Authors:  Simon Finfer; Rinaldo Bellomo; Suzanne McEvoy; Sing Kai Lo; John Myburgh; Bruce Neal; Robyn Norton
Journal:  BMJ       Date:  2006-10-13

10.  Cross-Sectional Guidelines for Therapy with Blood Components and Plasma Derivatives: Chapter 5 Human Albumin - Revised.

Authors: 
Journal:  Transfus Med Hemother       Date:  2016-05-03       Impact factor: 3.747

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.